Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;53(9):2208-2216.
doi: 10.1177/03635465251345823. Epub 2025 Jun 14.

Clinically Relevant Thresholds in Patient-Reported Outcomes: Do Patients' Expectations Evolve Over Long-term Follow-up?

Affiliations

Clinically Relevant Thresholds in Patient-Reported Outcomes: Do Patients' Expectations Evolve Over Long-term Follow-up?

Elizabeth G Walsh et al. Am J Sports Med. 2025 Jul.

Abstract

Background: Clinically relevant thresholds have been utilized to provide insight into postoperative functional status and patient satisfaction.

Purpose: To define and evaluate the minimal clinically important difference (MCID), Patient Acceptable Symptom State (PASS), and substantial clinical benefit (SCB) thresholds over the 2-, 5-, and 10-year timepoints for the modified Harris Hip Score (mHHS), Hip Outcome Score-Sports-Specific Subscale (HOS-SSS), and International Hip Outcome Tool (iHOT12).

Study design: Case series; Level of evidence, 4.

Methods: Data were retrospectively reviewed for patients who underwent primary hip arthroscopy from 2008 to 2021. The inclusion criteria comprised complete patient-reported outcome scores with anchor questions at the 2-, 5-, or 10-year timepoints. Groups were propensity score-matched 1 to 1 to 1 for these 3 timepoints to limit confounding variables. The PASS, SCB, and MCID thresholds were defined using the anchor-based method for the mHHS, HOS-SSS, and iHOT12.

Results: A total of 414 hips were included in the study. Area under the curve for all defined thresholds indicated acceptable to excellent discrimination. The thresholds for achieving the PASS, defined at the 2-, 5-, and 10-year respectively, were as follows: mHHS: 77.5, 85.5, and 78.5; HOS-SSS: 82.7, 76.4, and 67.7; and iHOT12: 67.4, 76.9, and 62.9. The percentage of patients achieving the PASS increased from 2 to 10 years, with the highest percentage at 10 years. The threshold for achieving the SCB was defined as follows: mHHS: 95, 99, and 88; HOS-SSS: 97, 80.9, and 90.5; and iHOT12: 89.4, 94.1, and 82.5. The percentage of patients achieving the SCB increased from 2 to 10 years. The mean changes required to achieve the MCID were defined as follows: mHHS: 7, 7.1, and 7.4; HOS-SSS: 10.6, 10.7, and 11.2; and iHOT12: (9.6, 9.7, -). The MCID and the percentage of patients achieving the MCID remained constant over 2 to 10 years.

Conclusion: Patients met the MCID, PASS, and SCB thresholds at high rates over 10 years. Based on the PASS and SCB thresholds, patient expectations for function evolved. Lower expectations at long-term follow-ups may result in a higher percentage of patients meeting certain thresholds, as evidenced in the mHHS, HOS-SSS, and iHOT12 in this cohort. Understanding the evolution of patient expectations may help interpret clinically relevant thresholds in future studies.

Keywords: Patient Acceptable Symptom State; femoroacetabular impingement syndrome; hip arthroscopy; minimal clinically important difference; patient expectations; substantial clinical benefit.

PubMed Disclaimer

Conflict of interest statement

One or more of the authors has declared the following potential conflict of interest or source of funding: B.G.D. has had ownership interests in the American Hip Institute and affiliates, North Shore Surgical Suites, and Munster Specialty Surgery Center; research support from Arthrex, Stryker, Smith & Nephew, and Ossur; consulting fees from Arthrex, Medacta, Stryker, and SI-Bone Inc; has received educational support from Arthrex, Stryker; speaking fees from Arthrex; travel and lodging from Arthrex and Stryker; food and beverage from Arthrex, DJO Global, Medacta, Stryker, Zimmer Biomet, DePuy Synthes Sales, Medtronic, Trice Medical, Medwest Associates, SI-Bone Inc, Xiros Inc, Intellijoint Surgical Inc, Electronic Waveform Lab Inc; royalties from Arthrex, DJO Global, Medacta, Orthomerica; patents with Arthrex, Orthomerica, and DJO Global. B.G.D. is Director of Hip Preservation at St. Alexius Medical Center and a board member for the American Hip Institute Research Foundation, Arthroscopy Association of North America Learning Center Committee, the Journal of Hip Preservation Surgery, Journal of Arthroscopy, AOSSM Research Committee, and ISHA – The Hip Preservation Society Executive Board. The American Hip Institute Research Foundation (American Orthopedic Foundation) funds research and is where the study was performed. R.Q-J. reports receiving travel reimbursement from Arthrex and Zimmer Biomet. A.H.K-R. reports receiving travel reimbursement from Arthrex and Zimmer Biomet. T.R.M. reports receiving travel reimbursement from Arthrex, Smith & Nephew, and Stryker. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. This study was performed in accordance with the ethical standards in the 1964 Declaration of Helsinki. This study was carried out in accordance with the relevant regulations of the United States Health Insurance Portability and Accountability Act. Details that might disclose the identity of the patients under study have been omitted. This study was approved by an Institutional Review Board (IRB ID: 5276).

Similar articles

Cited by

LinkOut - more resources